These data support the idea that biomarkers of CDK4/6 inhibitors for ESCC patients could include a loss of CDKN2A or CDKN2B rather than mutations of other cell cycle checkpoint genes in vitro. This evidence concerns the gene CDKN2B and esophageal squamous cell carcinoma.